Piper Sandler raised the firm’s price target on Acrivon Therapeutics (ACRV) to $8 from $6 and keeps an Overweight rating on the shares. The firm notes Acrivon hosted a virtual R&D event and updated Phase II data showing 105mg/m2 q2W ACR-368 achieved a 39% overall response rate among OncoSignature-positive endometrial cancer patients. Acrivon plans to submit an IND for newly unveiled CDK11 inhibitor ACR-6840 in Q4 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRV:
- Balancing Early Promise and Significant Uncertainty: Maintaining a Hold on Acrivon Therapeutics Amid Limited Data and Long-Dated Clinical Risk
- Focused Clinical Strategy and Accelerated Approval Path for ACR-368 in High-Need Serous Endometrial Cancer Underpin ACRV Buy Rating
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- Acrivon Showcases Promising Phase 2b Oncology Data Update
- Acrivon Therapeutics Stock (ACRV) Sinks despite Positive Cancer Trial Results